Table 4.
Studies of TPZ-based therapies as first-line Helicobacter pylori treatment.
| Studies | Study design | Sample size | Regimen | Duration (days) | Eradication rates (%) | |
|---|---|---|---|---|---|---|
| ITT | PP | |||||
| Choi YJ et al. (19) | RCT | 175 | TPZ 50 mg bid, AMO 1 g bid, CLA 500 mg bid | 7 | 62.9 | 69.3 |
| Park CH et al. (43) | Retrospective | 435 | TPZ 50 mg bid, AMO 1 g bid, CLA 500 mg bid | 14 | 78.6 | 85.5 |
| Jung BW et al. (44) | Retrospective | 620 | TPZ 50 mg bid, AMO 1 g bid, CLA 500 mg bid, MET 500 mg bid | 10 | 74.7 | 88.0 |
| Kwon YH et al. (45) | RCT | 79 | TPZ 50 mg bid, AMO 1 g bid, CLA 500 mg bid, MET 500 mg bid | 10 | 90.5 | 96.2 |
| Jung YS et al. (46) | Retrospective | 344 | TPZ 50 mg bid, AMO 1 g bid, CLA 500 mg bid | 14 | 76.7 | 83.4 |
| Kim JS et al. (26) | RCT | 108 | TPZ 50 mg bid, TRE 500 mg qid, MET 500 mg tid, B 300 mg qid | 14 | 80.0 | 90.2 |
| Park CH et al. (47) | Retrospective | 551 | TPZ 50 mg bid, AMO 1 g bid, CLA 500 mg bid | 14 | 76.4 | 84.5 |
| Park CH et al. (47) | Retrospective | 377 | TPZ 50 mg bid, AMO 1 g bid, CLA 500 mg bid, MET 500 mg bid | 10 | 85.9 | 91.1 |
| Kong Q et al. (48) | RCT | 184 | TPZ 50 mg bid, AMO 750 mg qid | 14 | 85.8 | 88.2 |
| Lee JW et al. (49) | RCT | 202 | TPZ 50 mg bid, AMO 1 g bid 5 days, CLA 500 mg bid and MET 500 mg bid 5 days | 10 | 87.1 | 87.1 |
| Lin X et al. (50) | RCT | 107 | TPZ 50 mg qd, AMO 1 g tid | 14 | 86.0 | 91.0 |
| Lin X et al. (50) | RCT | 107 | TPZ 50 mg bid, AMO 1 g tid | 14 | 86.0 | 93.8 |
| Cho JH (51) | Retrospective | 195 | TPZ 50 mg bid, AMO 1 g bid, CLA 500 mg bid | 14 | 82.9 | 95.8 |
| Cho JH (51) | Retrospective | 111 | TPZ 50 mg bid, AMO 1 g bid, CLA 500 mg bid, B 300 mg bid | 14 | 71.8 | 87.5 |
| Cho JH et al. (34) | RCT | 57 | TPZ 50 mg bid, AMO 1 g bid, CLA 500 mg bid, B 300 mg bid | 14 | 82.5 | 95.9 |
| Cho JH et al. (34) | RCT | 57 | TPZ 50 mg bid, AMO 500 mg qid, CLA 500 mg bid, B 300 mg bid | 14 | 87.7 | 98.0 |
| Kim JY et al. (52) | RCT | 193 | TPZ 50 mg bid, AMO 1 g bid, CLA 500 mg bid, B 300 mg bid | 7 | 78.8 | 88.9 |
| Present study | RCT | 160 | TPZ 50 mg bid, AMO 1 g tid | 14 | 85.5 | 87.2 |
| Present study | RCT | 159 | TPZ 50 mg bid, AMO 1 g bid, CLA 500 mg bid, B 300 mg tid | 14 | 86.3 | 87.3 |
ITT, intention-to-treat; PP, per-protocol; RCT, randomized controlled trial; AMO, amoxicillin; CLA, clarithromycin; MET, metronidazole; TRE, tetracycline; B, bismuth; TPZ, tegoprazan; qd, once daily; bid, twice daily; tid, three times daily; qid, four times daily.